person · Reporting owner
Oosthuizen Johannes Jacobus
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | EVP, Oncology & Int?l | May 05, 2026 | May 07, 2026 |
| Vylor Inc.VYLR · Entity 183857 | Director | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2029-05-05 | Direct | 10,605 |
Reported balance
After 2026-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-05 · Grant · Acquired 10,605 · Balance 10,605 F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.15 · Expires 2036-05-04 | Direct | 31,044 |
Reported balance
After 2026-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-05 · Grant · Acquired 31,044 · Balance 31,044 F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Common StockSEC Table I · non-derivative | Direct | 21,895.389 |
Reported balance
Holding disclosure · report date 2026-05-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 21,895.389 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
Vylor Inc.
Report date October 01, 2026 · Filed October 05, 2026
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 30, 2022 Filed Nov 1, 2022 20:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 913 | $100.77 | $92,003.01 |
DisclosureSEC source: 0001127602-22-024599 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,793.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 3,633 | $100.21 | $364,064.75 |
DisclosureSEC source: 0001127602-22-024599 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,880.881 Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 907 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013549 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,819 Underlying: Common Stock · 907 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 447 | $87.10 | $38,933.70 |
DisclosureSEC source: 0001127602-22-013549 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,513.881 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 907 | $87.10 | $78,999.70 |
DisclosureSEC source: 0001127602-22-013549 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,960.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 773 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013244 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 773 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 381 | $87.65 | $33,394.65 |
DisclosureSEC source: 0001127602-22-013244 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,053.881 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 773 | $87.65 | $67,753.45 |
DisclosureSEC source: 0001127602-22-013244 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,434.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 21,359 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013549 · form4.xml · derivative · entry 4 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,359 Underlying: Common Stock · 21,359 shares Expires 2032-05-02 F4 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013022 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866 Underlying: Common Stock · 866 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 427 | $88.69 | $37,870.63 |
DisclosureSEC source: 0001127602-22-013022 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,661.881 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 866 | $88.69 | $76,805.54 |
DisclosureSEC source: 0001127602-22-013022 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,088.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.